T cells are often called "assassins" or "killers" because they can orchestrate and carry out missions to hunt down bacteria, viruses, and cancer cells throughout the body. Mighty as they may be, recent research has shown ...
Mar 15, 2024
0
93
Making a personalized T cell therapy for cancer patients currently takes at least six months; scientists at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim have shown that the laborious ...
Mar 15, 2024
0
35
Scientists have developed an improved technique for reading the genetic material associated with the body's immune response to cancer, making it possible to study tissue samples that have been stored in archives for decades.
Mar 15, 2024
0
12
Targeting two brain tumor-associated proteins—rather than one—with CAR T cell therapy shows promise as a strategy for reducing solid tumor growth in patients with recurrent glioblastoma (GBM), an aggressive form of brain ...
Mar 13, 2024
0
89
Chimeric antigen receptor (CAR)-T cell therapy is a potent emerging weapon against cancer, altering patients' T cells so they can better find and destroy tumor cells. But CAR-T cell therapy doesn't work well in every cancer—including ...
Mar 1, 2024
0
9
CD19 chimeric antigen receptor (CAR) T-cell therapy seems feasible, safe, and efficacious for patients with different autoimmune diseases, according to a study published in the Feb. 22 issue of the New England Journal of ...
Feb 22, 2024
0
40
St. Jude Children's Research Hospital scientists have improved chimeric antigen receptor (CAR) T–cell immunotherapy for acute myeloid leukemia (AML), demonstrating better efficacy in the lab.
Feb 12, 2024
0
24
As the HIV virus glides up outside a human cell to dock and possibly inject its deadly cargo of genetic code, there's a spectacularly brief moment in which a tiny piece of its surface snaps open to begin the process of infection.
Feb 2, 2024
0
111
Researchers at the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital have developed a chimeric antigen receptor (CAR) T-cell therapy targeting T-cell ...
Jan 4, 2024
0
0
Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study published online Dec. 28 in Blood ...
Jan 4, 2024
0
0
